Morgan Stanley Upgrades Vir Biotechnology to Equal-Weight, Raises Price Target to $30
Morgan Stanley analyst Michael Ulz upgrades Vir Biotechnology (NASDAQ:VIR) from Underweight to Equal-Weight and raises the price target from $18 to $30.
European Official Says COVID-19 Booster Uptake Disappointing In The Region
Marco Cavaleri, the European Medicines Agency's (EMA) head of health threats and vaccines strategy, said the recent uptake of COVID-19 vaccine booster doses in the region has been "rather disappointing."
The European average rate of receiving booster doses was only 29% in the groups considered to be at the highest risk.
After Bill Gates Dumps Billions In Berkshire To Buy Microsoft, His Quiet Biotech Portfolio Has Made A New Trade
Bill Gates has two portfolios he makes trades from: the Bill & Melinda Gates Foundation and the Bill & Melinda Gates Foundation Trust.
Vir Biotechnology Presenting New Data Evaluating the Potential for VIR-2218 and VIR-3434 to Achieve a Functional Cure for Chronic Hepatitis B Virus (HBV) Infection at AASLD Liver Meeting
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new data from its robust hepatitis B virus (HBV) portfolio aimed at achieving a functional cure.
Block, MasTec, Universal Display And Some Other Big Stocks Moving Higher On Friday
U.S. stocks traded higher, with the Dow Jones gaining more than 400 points on Friday. Here are some big stocks recording gains in today’s session.
Needham Maintains Buy on Vir Biotechnology, Lowers Price Target to $32
Needham analyst Joseph Stringer maintains Vir Biotechnology (NASDAQ:VIR) with a Buy and lowers the price target from $35 to $32.
SVB Leerink Maintains Outperform on Vir Biotechnology, Raises Price Target to $45
SVB Leerink analyst Roanna Ruiz maintains Vir Biotechnology (NASDAQ:VIR) with a Outperform and raises the price target from $40 to $45.